Want to see TKNO full AI Analyst Report?
TKNO Stock Chart & Stats
$4.85
-$0.12(-2.41%)
At close: 4:00 PM EDT
$4.85
-$0.12(-2.41%)
Day’s Range― - ―
52-Week Range$1.91 - $7.84
Previous Close$4.85
Volume119.72K
Average Volume (3M)318.88K
Market Cap
$400.51M
Enterprise Value$314.62
Total Cash (Recent Filing)$17.44M
Total Debt (Recent Filing)$27.41M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Nov 05, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding53,688,248
10 Day Avg. Volume259,294
30 Day Avg. Volume318,881
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.96
Price to Sales (P/S)5.02
P/FCF Ratio-20.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.67Price Target Upside58.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$45.95M
Bulls Say, Bears Say
Bulls Say
Clinical Solutions GrowthBroad-based growth across more customers suggests improving adoption of the company’s solutions rather than reliance on one order. If sustained, greater clinical workflow penetration can expand recurring demand and support future manufacturing scale.
Manufacturing ScaleLarger batches and automation can increase production capacity while lowering labor intensity per unit. These process improvements may support margin durability and allow the company to handle higher customer volumes without equivalent increases in operating resources.
Improving Gross MarginImproving gross margin and adjusted EBITDA indicate operational progress as revenue scales, even though profitability remains negative. Continued gains would strengthen the path toward the stated adjusted EBITDA breakeven threshold and reduce future funding needs.
Bears Say
Persistent UnprofitabilityThe company remains structurally dependent on external resources because losses and cash burn persist despite improvement from prior years. Continued negative cash generation can constrain investment, weaken the equity base, and increase financing risk.
High Fixed-Cost StructureThe high fixed-cost model means meaningful revenue growth is required before incremental sales translate into positive cash earnings. Any delay in reaching the revenue threshold could prolong losses and make profitability sensitive to demand volatility.
Core Segment SoftnessLab Essentials appears to provide a less robust growth base than Clinical Solutions, with modest revenue expansion and fewer customers. Persistent weakness could limit diversification, reduce operating leverage, and increase reliance on newer growth initiatives.
Alpha Teknova News
TKNO FAQ
What was Alpha Teknova’s price range in the past 12 months?
Alpha Teknova lowest stock price was $1.91 and its highest was $7.84 in the past 12 months.
What is Alpha Teknova’s market cap?
Alpha Teknova’s market cap is $400.51M.
When is Alpha Teknova’s upcoming earnings report date?
Alpha Teknova’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were Alpha Teknova’s earnings last quarter?
Alpha Teknova released its earnings results on Aug 05, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.084 by $0.024.
Is Alpha Teknova overvalued?
According to Wall Street analysts Alpha Teknova’s price is currently Undervalued.
Does Alpha Teknova pay dividends?
Alpha Teknova does not currently pay dividends.
What is Alpha Teknova’s EPS estimate?
Alpha Teknova’s EPS estimate is -0.08.
How many shares outstanding does Alpha Teknova have?
Alpha Teknova has 53,688,248 shares outstanding.
What happened to Alpha Teknova’s price movement after its last earnings report?
Alpha Teknova reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.084. Following the earnings report the stock price went up 16.399%.
Which hedge fund is a major shareholder of Alpha Teknova?
Currently, no hedge funds are holding shares in TKNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Teknova Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (58.08% Upside)
$7.67 (58.08% Upside)
Blogger Sentiment
Neutral
TKNO Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 592.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 17.0%
Last 30 Days ▲ 17.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.22%
Trailing 12-Months
Company Description
Alpha Teknova
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
TKNO Company Deck
TKNO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone: the company reported solid top-line growth (13% YoY), a pronounced 85% increase in Clinical Solutions, improved gross margin and adjusted EBITDA, operational scaling initiatives, and disciplined commercial investments aimed at driving ~20% growth in 2027. However, material risks remain including a persistent GAAP net loss, continued negative adjusted EBITDA, modest Lab Essentials growth, high fixed-cost structure with a roughly 70% marginal cash drop-through, and dependence on broader biotech funding recovery. Management reiterated a conservative 2026 guide while outlining a credible plan for improved profitability and growth in 2027.View all TKNO earnings summariesTKNO Stock 12 Month Forecast
Average Price Target
$7.67
▲(58.08% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
1.31% Insiders
2.50% Mutual Funds
7.24% Other Institutional Investors
84.29% Public Companies and
Individual Investors